

CWHM-12

Chemical Properties


CAS No. : 1564286-55-0

Formula: C₂₆H₃₂BrN₅O₆

Molecular Weight: 590.47

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	CWHM-12 is a potent inhibitor of α V integrins, with IC ₅₀ values of 0.2, 0.8, 1.5, and 1.8 nM for α V β 8, α V β 3, α V β 6, and α V β 1, respectively.
Targets(IC ₅₀)	Integrin
In vitro	CWHM-12 also less potently inhibits α V β 5 (IC ₅₀ : 61 nM) and α IIb β 3/ α 2 β 1/ α 10 β 1 (IC ₅₀ >5000 nM). CWHM-12 demonstrates high potency against all of the five possible β subunit binding partners (α V β 1, α V β 3, α V β 5, α V β 6, and α V β 8) in in vitro ligand-binding assays, with somewhat less potency against α V β 5 than against the other α V integrins.
In vivo	Mice are treated with CCl ₄ for 3 weeks to establish fibrotic disease and then treated with CWHM-12 or vehicle for the final 3 weeks of CCl ₄ . CWHM-12 significantly reduces liver fibrosis even after the fibrotic disease has been established. Digital image quantitation demonstrates significantly reduced p-SMAD3 signaling in the livers of CWHM-12 treated mice compared to controls, demonstrating that the protection from CCl ₄ -induced hepatic fibrosis observed in CWHM-12 treated mice is due at least in part to a reduction in TGF- β activation by α V integrins. Besides, the administration of CWHM-12 significantly inhibited the progression of pulmonary fibrosis.
Kinase Assay	Functions of integrins α V β 1, α V β 8, α 2 β 1, and α 10 β 1 are measured using cell-free receptor-ligand interaction assays using purified recombinant human integrins. Ligands used are human fibronectin for α V β 1, human LAP for α V β 8, bovine collagen II for α 2 β 1, and murine laminin I for α 10 β 1. 96-well plates are coated with the predetermined optimal concentration of ligand overnight, washed 3X with TBS+++ (25 mM Tris pH7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl ₂ , 1 mM MnCl ₂ , 1mM CaCl ₂), and blocked with TBS+++ /1%BSA. Purified integrin is diluted in TBS+++ /0.1%BSA with or without compounds (e.g., CWHM-12), and the solution added to empty wells of the washed ligand-coated plate according to a standard template, with each sample repeated in triplicate. After incubation for 2 hr at room temperature, the plate is washed 3X with TBS+++ . Biotin-labeled antibody against the α V subunit (α V β 1, α V β 8 assays) or β 1 subunit (α 2 β 1, α 10 β 1 assays) is applied for 1 hr. The plate is washed 3X with TBS/0.1% BSA. Streptavidin-conjugated horseradish peroxidase is added to the wells, and the plate incubated for 20 min at room temperature. Following a 3X TBS+++ wash, bound integrin is detected using streptavidin-conjugated horseradish peroxidase and TMB substrate with absorbance measured at 650 nm. For assay of α IIb β 3 (IIbIIIa) function, plates are coated with the purified human integrin overnight, washed 3X with TBS+++ ,

Kinase Assay	and blocked with TBS+++ / 1% BSA. Alexa Fluor647-labeled purified human fibrinogen is diluted in TBS+++ / 0.1% BSA with or without compounds, and the solutions are added to the integrin-coated plate. After 2 hr incubation, the plate is washed 3X with TBS+++ , and the bound ligand is detected by absorbance measured at 640/668nm. For all assays, concentration-response curves are constructed by non-linear regression analysis and IC50 values are calculated using GraphPad Prism software.
Cell Research	The stably transfected human 293 cells over-expressing human $\alpha\beta3$ or $\alpha\beta5$ are pre-incubated in HBSS buffer containing 200 μM MnCl_2 for 30 min at 37°C with 3-fold dilutions of compound (e.g., CWHM-12). Each sample is then added to triplicate wells of a 96-well plate which has been coated overnight at 4°C with a predetermined optimal concentration of purified vitronectin, washed, blocked by 1 hr incubation with BSA, and washed again. Cells are allowed to attach for 30 min at 37°C, and non-adherent cells are removed by washing. Remaining attached cells are measured by endogenous alkaline phosphatase activity using para-nitrophenyl phosphate and reading absorbance signal at 405 nM. The same procedure is used to measure adhesion of $\alpha\beta6$ -expressing human HT-29 cells to purified human latency-associated peptide, and $\alpha5\beta1$ -expressing human K562 cells to human plasma fibronectin. In all cell-based assays, binding by the expected integrin is verified by the testing activity of corresponding isotype-matched positive (function-blocking) and negative control antibodies.
Animal Research	The mTmG (Td tomato/EGFP) and Ai14 (Rosa-CAG-LSL-tdTomato-WPRE) mice are used and crossed with Pdgfrb-Cre mice. Wild type C57/BL6 mice, Itgavflox/flox mice, and itgb8flox/flox mice are used. Mice used for all experiments are 8-12 weeks old and are housed under specific pathogen-free conditions. For all studies, CWHM-12 and CWHM-96 are solubilized in 50% DMSO (in sterile water) and dosed to 100 mg/kg/day. Drug or vehicle (50% DMSO) is delivered by implantable ALZET osmotic minipumps. For CCL4-induced fibrosis, pumps are inserted subcutaneously either before the first dose of CCL4 (prophylactic) or after 3 weeks of treatment (therapeutic) and livers are harvested after 6 weeks. For Bleomycin-induced fibrosis pumps are inserted 14 days after treatment with Bleomycin or saline and lungs are harvested at 28 days.

Solubility Information

Solubility	DMSO: 150 mg/mL (254.03 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (16.94 mM), Solution. 10% DMSO+90% Saline: < 10 mg/mL (16.94 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6936 mL	8.4678 mL	16.9357 mL
5 mM	0.3387 mL	1.6936 mL	3.3871 mL
10 mM	0.1694 mL	0.8468 mL	1.6936 mL
50 mM	0.0339 mL	0.1694 mL	0.3387 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Henderson NC, et al. Targeting of α v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481